Effect of prostacyclin on renal kallikrein release in man.
The aim of this research was to study exogenous prostacyclin effect on urinary kallikrein excretion (UKK) in man, to define whether prostacyclin-induced renin release and/or endogenously released cyclooxygenase products were responsible for prostacyclin-induced enhancement of UKK, to determine furosemide effect on UKK. Prostacyclin was infused in eight healthy men and repeated after propranolol and indomethacin treatment. Prostacyclin caused a dose-dependent increase of UKK. Pretreatment with propranolol and indomethacin did not affect prostacyclin-induced enhancement of UKK, although it reduced absolute values of plasma renin activity. Furosemide increased UKK and simultaneously urinary 6-keto-prostaglandin F1 alpha. We conclude that prostacyclin induces an increase in UKK in a dose-dependent manner; furosemide-induced renal prostacyclin synthesis is temporally related to enhancement of UKK; partial dissociation of UKK from plasma renin activity under propranolol and indomethacin treatment and in response to furosemide might suggest a direct effect of prostacyclin on UKK.
D015121:6-Ketoprostaglandin F1 alpha / Q000494:pharmacology; D000328:Adult; D011464:Epoprostenol / Q000494:pharmacology*; D005665:Furosemide / Q000494:pharmacology; D006801:Humans; D007213:Indomethacin / Q000494:pharmacology; D007610:Kallikreins / Q000378:metabolism* / Q000652:urine; D007668:Kidney / Q000187:drug effects* / Q000378:metabolism; D008297:Male; D011433:Propranolol / Q000494:pharmacology; D012083:Renin / Q000097:blood
D015121:6-Ketoprostaglandin F1 alpha; D005665:Furosemide; D011433:Propranolol; D011464:Epoprostenol; D007610:Kallikreins; D012083:Renin; D007213:Indomethacin